{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-002849","form_type":"8-K","ticker":"TEVA","cik":"0000818686","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.389659+00:00","generated_at":"2026-05-22T10:00:33.702200+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Teva Q1 2025: revenue $3.9B (+5% LC), Non-GAAP EPS $0.52 (+8% YoY); raises FY outlook","bullets":["Q1 revenue $3.9B (+5% local currency, +2% reported); GAAP EPS $0.18, Non-GAAP EPS $0.52 (vs $0.48 YoY).","Key innovative products grew ~39% YoY: AUSTEDO $411M (+39%), AJOVY $139M (+26%), UZEDY $39M.","FY2025 guidance raised: Non-GAAP EPS $2.45-$2.65 (midpoint +$0.10), Non-GAAP op income $4.3-$4.6B (+$200M at low end).","Generics grew in all regions (U.S. +5%, Europe +1%, Intl +2% in local currency).","On track for 30% operating margin by 2027; announces $700M net savings program."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-002849","json":"https://secwatch.observer/filing/0001171843-25-002849.json","markdown":"https://secwatch.observer/filing/0001171843-25-002849.md","text":"https://secwatch.observer/filing/0001171843-25-002849.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818686/000117184325002849/0001171843-25-002849-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818686/000117184325002849/f8k_050725.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T10:00:33.702200+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}